Search Within

Monica Nancy Fornier

Formats
  1. Journal Article (92)
  2. Meeting Abstract (63)
  3. Review (2)
  4. Editorial (1)
Groups
  1. Breast Medicine Service (158)
  2. Department of Medicine (158)
  3. Solid Tumor Oncology Division (158)
  4. Survivorship Research (158)
  5. Epidemiology and Biostatistics (64)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (58)

More Groups

People
  1. Clifford Hudis (72)
  2. Larry Norton (53)
  3. Chau Dang (38)
  4. Gabriella D'Andrea-Carlino (38)
  5. Andrew Seidman (37)
  6. Diana Lake (36)

More People

Years
  1. 2024 (3)
  2. 2023 (1)
  3. 2022 (1)
  4. 2021 (3)
  5. 2020 (6)
  6. 2019 (4)

More Years

Publications
  1. Journal of Clinical Oncology (34)
  2. Breast Cancer Research and Treatment (15)
  3. Annals of Oncology (11)
  4. Cancer Research (11)
  5. Clinical Breast Cancer (8)
  6. Clinical Cancer Research (7)

More Publications

Publishers
  1. American Society of Clinical Oncology (35)
  2. Springer (21)
  3. American Association for Cancer Research (19)
  4. Elsevier Inc. (17)
  5. Oxford University Press (13)
  6. Wiley Blackwell (10)

More Publishers

Results (158)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Ki67 changes and PEPI score in the LORELEI trial: A phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative early-stage breast cancer
    Meeting Abstract

    de Azambuja, E.; Saura, C.; Nuciforo, P.; Frantal, S.; Oliveira, M.; Zardavas, D.; Jallitsch-Halper, A.; de la Pena, L.; Dubsky, P.; Lombard, J. M.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save
  • Phase II study of gemcitabine (G), trastuzumab (H), and pertuzumab (P) for HER2-positive metastatic breast cancer (MBC) after prior pertuzumab-based therapy
    Meeting Abstract

    Iyengar, N. M.; Smyth, L. M.; Lake, D.; Gucalp, A.; Singh, J. C.; Traina, T. A.; DeFusco, P. A.; Dickler, M. N.; Fornier, M. N.; Goldfarb, S. B.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Primary results of LORELEI: A phase II randomized, double-blind study of neoadjuvant letrozole (LET) plus taselisib versus LET plus placebo (PLA) in postmenopausal patients (pts) with ER+/HER2-negative early breast cancer (EBC)
    Meeting Abstract

    Saura, C.; de Azambuja, E.; Hlauschek, D.; Oliveira, M.; Zardavas, D.; Jallitsch-Halper, A.; de la Pena, L.; Nuciforo, P.; Ballestrero, A.; Fornier, M. N.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-positive metastatic breast cancer after prior pertuzumab-based therapy
    Meeting Abstract

    Iyengar, N. M.; Smyth, L. M.; Lake, D.; Gucalp, A.; Singh, J. C.; Traina, T. A.; Defusco, P.; Dickler, M. N.; Fornier, M. N.; Goldfarb, S. B.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Less intense dosing schedule for a bone-modifying agent
    Journal Article

    Fornier, M. N.
    JAMA Oncology (2017)

    Fulltext@MSK | Save
  • Assessing fracture risk in early stage breast cancer patients treated with aromatase-inhibitors: An enhanced screening approach incorporating trabecular bone score
    Journal Article

    Mariotti, V.; Page, D. B.; Davydov, O.; Hans, D.; Hudis, C. A.; Patil, S.; Kunte, S.; Girotra, M.; Farooki, A.; Fornier, M. N.
    Journal of Bone Oncology (2017)

    Fulltext@MSK | Save
  • Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-Positive metastatic breast cancer after prior pertuzumab-based therapy
    Meeting Abstract

    Iyengar, N. M.; Smyth, L.; Lake, D.; Gucalp, A.; Singh, J. C.; Traina, T. A.; DeFusco, P.; Dickler, M. N.; Fornier, M. N.; Goldfarb, S.; more...
    Cancer Research (2017)

    Fulltext@MSK | Save
  • Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-positive metastatic breast cancer after prior pertuzumab-based therapy
    Meeting Abstract

    Iyengar, N. M.; Smyth, L.; Lake, D.; Gucalp, A.; Singh, J.; Traina, T. A.; Defusco, P.; Dickler, M. N.; Fornier, M.; Goldfarb, S.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • A pilot study of dose-dense paclitaxel with trastuzumab and lapatinib for node-negative HER2-overexpressed breast cancer
    Journal Article

    Iyengar, N. M.; Fornier, M. N.; Sugarman, S. M.; Theodoulou, M.; Troso-Sandoval, T. A.; D'Andrea, G. M.; Drullinsky, P. R.; Gajria, D.; Goldfarb, S. B.; Comen, E. A.; more...
    Clinical Breast Cancer (2016)

    Fulltext@MSK | Save
  • Osteonecrosis of the jaw in patients treated with denosumab for metastatic tumors to the bone: A series of thirteen patients
    Journal Article

    Owosho, A. A.; Blanchard, A.; Levi, L.; Kadempour, A.; Rosenberg, H.; Yom, S. K.; Farooki, A.; Fornier, M.; Huryn, J. M.; Estilo, C. L.
    Journal of Cranio-Maxillofacial Surgery (2016)

    Fulltext@MSK | Save